President Trump announced Friday that all 50 states, Puerto Rico, and DC have opted into his “most favored nations’’ drug-price initiative, a move he says will lower prescription costs for Medicaid recipients by matching rates paid in eight high-income nations, including Canada, Germany, Japan, and the UK. The announcement came as part of a broader push from the administration to highlight healthcare achievements ahead of the midterms.
The initiative forces 26 major pharmaceutical companies to enact special drug pricing. Trump said “They all succumbed to the dollar” of US states and others joining the initiative. He said “This will save states billions and billions of dollars per year on drugs,” and “I mean, this one thing alone should win us the midterm.”
The Numbers Behind the Plan
The White House Council Economic Advisers estimates the initiative will save state Medicaid programs $64 billion over 10 years. The broader MFN initiative is estimated to save the government $529 billion over a decade. Medicaid covers roughly 70 million Americans through state-administered programs.
Big Pharma agreed to offer discounts for certain drugs for Americans without insurance on the “TrumpRx” platform. The discounts apply to a subset of medications, not all prescriptions.
What the States Actually Get
Dr. Mehmet Oz, Medicare and Medicaid administrator, said “We are rescuing state budgets with this program.” He added that “The $50 billion in pharmaceutical prices that they are paying after rebates is crowding out schools and roads and long-term care and rural care.”
Health and Human Services Secretary Robert F. Kennedy Jr. framed the initiative as consistent with what “my party was promising and prioritizing for decades.” He pointed to “President Trump just mentioned that the poverty levels have dropped to the lowest level in history during his term” and said “That was the signature imperative for our party, and yet President Trump has actually achieved that in two short years.”
Where the paper stands
The paper backs the states’ ability to bargain with drugmakers on their own terms and is against an administration that uses federal leverage to force uniformity across all 50 states. The initiative forces 26 major pharmaceutical companies to enact special drug pricing, and the administration is presenting it as a done agreement with all parties committed. The paper’s position is that power should not gather in one place, whether an agency or an office, and that federal mandates on private life are a danger.
The initiative is a case of the administration using its power to force conformity rather than letting each state negotiate its own deals with drugmakers. The White House Council Economic Advisers estimates the initiative will save state Medicaid programs $64 billion over 10 years, but the paper wants decisions about healthcare policy to be made closer to the people affected by them.
The paper would prefer a system where states bargain with drugmakers directly, rather than having the federal government dictate uniform terms for every state. The reader should watch for further concentration of power in Washington, whichever party holds it.
Key Facts Box
- All 50 states, Puerto Rico, and DC have opted into the MFN initiative
- Initiative matches drug prices paid in eight high-income nations, including Canada, Germany, Japan, and the UK
- 26 major pharmaceutical companies forced to enact special drug pricing
- White House Council Economic Advisers estimates $64 billion in Medicaid savings over 10 years
- Broader MFN initiative estimated to save $529 billion over a decade
- Medicaid covers roughly 70 million Americans
- Pharma offers discounts on TrumpRx platform for Americans without insurance
What Happens Next
The initiative rolls out with all 50 states, Puerto Rico, and DC on board. The discounts apply to Medicaid recipients first, with the TrumpRx platform serving those without insurance later.
The administration has pushed this as a signature achievement heading into the midterms. Whether the savings materialize as promised remains to be seen.
The White House has presented the deal as a done agreement, with all parties committed. The states have opted in, and the drug companies have agreed to the terms. Whether the savings match the promises remains to be seen.
Source material: “Trump’s ‘favored nations’ drug discount gets buy-in from all 50 states — and will save billions for Medicaid,” the New York Post.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.